Would you consider use of single-agent lenvatinib for advanced renal cell cancer after first-line therapy?
Data reported by Motzer et al Lancet 2015 demonstrated a statistically superior PFS benefit of lenvatinib monotherapy over everolimus alone. In particular, would you consider lenvatinib monotherapy if patients were started on combination therapy and experienced toxicity attributable to everolimus?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on
I have not used this combination because I feel more data is needed. Previous mTOR+VEGF combinations failed to improve outcomes when studied in large phase 3 trials, so I am a bit skeptical of these results and waiting for the phase 3 to ready out. In addition, there is significant toxicity wtih thi...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on
Monotherapy with lenvatinib is certainly active as seen in the phase 2 study so yes I think it is a reasonable choice. I agree TKI + I/O is active but would caution against doing this outside of a clinical trial.
Join for free or sign in to see the full answer